2629 Stock Overview

A micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. More details

2629 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Negative shareholders equity

Revenue has declined by 16.1% over the past year

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Mirxes Holding Company Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mirxes Holding
Historical stock prices
Current Share Price	HK$30.00
52 Week High	HK$31.95
52 Week Low	HK$29.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	28.76%

Recent updates

Shareholder Returns

	2629	HK Medical Equipment	HK Market
7D	n/a	1.1%	1.8%
1Y	n/a	10.2%	16.9%

Return vs Industry: Insufficient data to determine how 2629 performed against the Hong Kong Medical Equipment industry.

Return vs Market: Insufficient data to determine how 2629 performed against the Hong Kong Market.

Price Volatility

Is 2629's price volatile compared to industry and market?
2629 volatility
2629 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.1%
Market Average Movement	7.9%
10% most volatile stocks in HK Market	15.2%
10% least volatile stocks in HK Market	4.2%

Stable Share Price: 2629's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 2629's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	352	Lihan Zhou	mirxes.com

Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products.

Mirxes Holding Company Limited Fundamentals Summary

How do Mirxes Holding's earnings and revenue compare to its market cap?
2629 fundamental statistics
Market cap	HK$7.89b
Earnings (TTM)	-HK$723.14m
Revenue (TTM)	HK$158.86m

49.7x

P/S Ratio

-10.9x

P/E Ratio

Is 2629 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2629 income statement (TTM)
Revenue	US$20.28m
Cost of Revenue	US$11.40m
Gross Profit	US$8.89m
Other Expenses	US$101.21m
Earnings	-US$92.33m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.35
Gross Margin	43.82%
Net Profit Margin	-455.20%
Debt/Equity Ratio	-117.8%

How did 2629 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/24 12:05
End of Day Share Price	2025/05/23 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mirxes Holding Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Mirxes Holding SEHK:2629 Stock Report